Adaptimmune Therapeutics ADAP reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics beat estimated earnings by 77.27%, reporting an EPS of $-0.05 versus an estimate of $-0.22.
Revenue was up $3.14 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.18 which was followed by a 4.95% drop in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
---|---|---|---|---|
EPS Estimate | 0.14 | -0.26 | -0.24 | -0.25 |
EPS Actual | -0.04 | -0.30 | -0.24 | -0.24 |
Revenue Estimate | 96.45M | 1.37M | 1.36M | 1.83M |
Revenue Actual | 1.42M | 1.20M | 3.10M | 434.00K |
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.